Table 2.

Effect of Different Anti–Class I MoAbs on Binding of MoAb90, Proliferation, and Apoptosis of 3-Day PHA-Activated PBL

AntibodiesSpecificity*Binding Competition% Inhibition of Proliferation% Specific Apoptosis
90 α1 (A, B, C, G) 66 43.4 ± 5.1 38.6 ± 3.5 
YTH862 α1 (A, B, C, G) 65 95.6 ± 3.2 51.5 ± 4.6 
B9.12.1 α1 (A, B, C) 15 21.9 ± 4.0 9.2 ± 2.5 
W6.32 α2 (A, B, C) 4.1 ± 4.3 0.9 ± 1.1 
TP25.99 α3 (A, B, C) 11.1 ± 3.0 10.9 ± 2.7 
HC10 α1/α2 (B) 0.7 ± 3.8 0.1 ± 0.1 
B1.23.2 ND (B, C) 1.3 ± 2.9 0.5 ± 2.3 
B1.G6 β2m/α1 37 21.0 ± 4.5 3.0 ± 0.6 
BE104 β2m 54 6.4 ± 1.2 0.2 ± 0.7 
IgG2a control ND 0.3 ± 2.4 0.0 ± 0.0 
IgG1 control ND 0.9 ± 2.5 0.0 ± 0.0 
AntibodiesSpecificity*Binding Competition% Inhibition of Proliferation% Specific Apoptosis
90 α1 (A, B, C, G) 66 43.4 ± 5.1 38.6 ± 3.5 
YTH862 α1 (A, B, C, G) 65 95.6 ± 3.2 51.5 ± 4.6 
B9.12.1 α1 (A, B, C) 15 21.9 ± 4.0 9.2 ± 2.5 
W6.32 α2 (A, B, C) 4.1 ± 4.3 0.9 ± 1.1 
TP25.99 α3 (A, B, C) 11.1 ± 3.0 10.9 ± 2.7 
HC10 α1/α2 (B) 0.7 ± 3.8 0.1 ± 0.1 
B1.23.2 ND (B, C) 1.3 ± 2.9 0.5 ± 2.3 
B1.G6 β2m/α1 37 21.0 ± 4.5 3.0 ± 0.6 
BE104 β2m 54 6.4 ± 1.2 0.2 ± 0.7 
IgG2a control ND 0.3 ± 2.4 0.0 ± 0.0 
IgG1 control ND 0.9 ± 2.5 0.0 ± 0.0 

Abbreviation: ND, not determined.

*

Specificity represents the different domains of HLA class I molecule or β2m and the class I locus product when determined by immunoprecipitation from mouse-transfected fibroblasts.

Results are expressed as percentage of MFI decrease by addition of biotinylated MoAb90 as described in Materials and Methods.

Cells were cultured during 3 days with PHA (10 μg/mL) and then treated with different MoAbs for 24 hours. Apoptosis was assessed by Hoechst 33342 staining and inhibition of proliferation was determined as the decrease of [3H]TdR incorporation as described in Materials and Methods. Results are expressed as mean ± SD of five independent experiments.

or Create an Account

Close Modal
Close Modal